- Activity pressure is positive on the latest completed week.
MOLN
EBS
Week ended 07 Aug 2026
Weekly Investor Report
Molecular Partners AG · Healthcare · Biotechnology
Latest close
3.24 CHF
-2.1%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is -1.6% below the Trend Line and sits at 44.6% of its 52-week range. The latest completed week returned -2.1%, after a 0.3% four-week move. The latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal.
Setup score
39
out of 100
Latest Close
3.24 CHF
7 Aug 2026
1W Return
-2.1%
latest completed week
4W Return
0.3%
short-term follow-through
12W Return
9.1%
quarterly tape
Trend Breadth
36.5%
19 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 41.86% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-2.1%
Latest completed week; four-week move 0.3%.
Indicator stack
20/65
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Recent
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 41.86%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
49/100
18 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -1.6% below the Trend Line and sits at 44.6% of its 52-week range. The latest completed week returned -2.1%, after a 0.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1612-week average 0.17
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.16Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 0.3% over four weeks, 9.1% over 12 weeks, and 10.2% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year19
Trend breadth36.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.21Latest activity-pressure read.
Pressure change140.0%Four-week change in activity pressure.
Leadership-8.84Latest relative-leadership reading.
RS change-9.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment49/100
Weighted news tone is neutral across 18 relevant articles.
3 positive · 14 neutral · 1 negativePatient CapitalRecent
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-18.2%Distance below the 52-week high.
13-week volatility3.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2611 weeks finished lower.
Best week+8.5%Week of 20 Feb.
Worst week-14.2%Week of 13 Mar.
Latest week-2.1%Week of 7 Aug.
Shape of recent returns
Strong gains6
Modest gains7
Flat weeks2
Modest losses6
Sharp losses5
Recent vol3.5%13-week weekly-return volatility.
Base vol5.0%52-week weekly-return volatility.
Up/down split24/24Count of positive and negative weeks in the 52-week window.
Average skew4.5% / -3.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorCH Healthcare
4-week rank22 / 40
Group average2.0%
Trend breadth52.5%
Trend52.5%active weekly trend signals
MD62.5%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
IndustryCH Biotechnology
4-week rank5 / 11
Group average2.2%
Trend breadth36.4%
Trend36.4%active weekly trend signals
MD36.4%positive activity pressure
RS36.4%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape35/100
Trend, activity pressure, participation, and risk combine to a 35/100 tape read.
Indicator analysis15/100Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.
Activity pressure 0.16; No reversal markers Next-Week ExpectancyNegative 41.86%Next-week expectancy is negative with a 41.86% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100No published factor snapshot is available yet.
Patient CapitalRecentActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks Sentiment49/100Weighted news tone is neutral across 18 relevant articles.
Molecular Partners AG (MOLN) Valuation: PE, PB & Fair Value Analysis Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 3.24 CHF | -2.1% | 3.29 CHF | 3.84 CHF | 0.21 | -8.84 | 52.9K | Off |
| 31 Jul 2026 | 3.31 CHF | 4.1% | 3.29 CHF | 3.86 CHF | 0.14 | -5.77 | 66.6K | Off |
| 24 Jul 2026 | 3.18 CHF | 0.6% | 3.30 CHF | 3.87 CHF | -0.11 | -9.54 | 66.0K | Off |
| 17 Jul 2026 | 3.16 CHF | -2.2% | 3.30 CHF | 3.88 CHF | -0.38 | -10.56 | 36.6K | Off |
| 10 Jul 2026 | 3.23 CHF | 1.6% | 3.32 CHF | 3.90 CHF | -0.54 | -8.09 | 88.0K | Off |
| 3 Jul 2026 | 3.18 CHF | 0.0% | 3.32 CHF | 3.92 CHF | -0.93 | -10.81 | 19.2K | Off |
| 26 Jun 2026 | 3.18 CHF | 2.9% | 3.33 CHF | 3.93 CHF | -1.16 | -9.42 | 5.7K | Off |
| 19 Jun 2026 | 3.09 CHF | 2.0% | 3.33 CHF | 3.95 CHF | -1.21 | -9.59 | 21.9K | Off |
| 12 Jun 2026 | 3.03 CHF | 1.0% | 3.33 CHF | 3.96 CHF | -1.15 | -11.06 | 8.5K | Off |
| 5 Jun 2026 | 3.00 CHF | -4.5% | 3.34 CHF | 3.98 CHF | -1.09 | -10.08 | 12.7K | Off |
| 29 May 2026 | 3.14 CHF | -0.3% | 3.35 CHF | 4.00 CHF | -0.96 | -7.08 | 61.1K | Off |
| 22 May 2026 | 3.15 CHF | 6.1% | 3.34 CHF | 4.02 CHF | -0.89 | -6.73 | 171.4K | Off |
| 15 May 2026 | 2.97 CHF | -8.0% | 3.33 CHF | 4.04 CHF | -0.78 | -10.46 | 152.3K | Off |
| 8 May 2026 | 3.23 CHF | 0.6% | 3.33 CHF | 4.06 CHF | -0.69 | -2.04 | 107.3K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.